Pioneering antibody-drug conjugates targeting the tumour microenvironment to deliver transformative new therapies in oncology

ongoing

Oncomatryx Biopharma SL (ONCOMATRYX) is a cutting-edge biotechnology company established in 2010 in Bilbao, Spain, with the mission to pioneer and develop novel precision drugs targeting the tumour microenvironment for indications of high unmet need. We strive to change the paradigm in the treatment of some of the most aggressive metastatic solid tumors, by neutralizing the immunosuppressive influence of the tumour microenvironment on cancer cells. To achieve this goal, we have developed a comprehensive pipeline of antibody-drug conjugates (ADCs) and human-derived proteins targeting stroma cells in the tumor microenvironment. Our lead candidate, OMTX705, has demonstrated promising safety and efficacy in preclinical models and is currently undergoing Phase I clinical trials for colorectal, pancreatic, lung, and sarcoma cancers. The global market for ADCs is expanding rapidly, with a projected $140 billion opportunity over the next 15 years. ONCOMATRYX aims to leverage this growth through a business strategy focused on out-licensing its assets to pharmaceutical partners for large-scale clinical development and commercialization. The company has already secured a licensing agreement with InxMed for the East Asian market and anticipates a €700M licensing deal for North America, Europe, and Japan upon successful completion of Phase II trials. To advance OMTX705 into Phase Ib and II clinical trials, ONCOMATRYX seeks EIC Accelerator funding, combining a €2.5M grant and a €10M equity investment. This funding will enable parallel execution of Phase Ib studies, accelerate clinical development, and strengthen the company’s market positioning for strategic partnerships. Ultimately, EIC support will be instrumental in achieving key milestones, securing major licensing deals, and driving ONCOMATRYX’s long-term success in transforming cancer treatment.